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Background: Cystic fibrosis (CF) is characterized by chronic bacterial broncho-pulmonary infection. Although intravenous (IV) antibiotic
therapy is regarded as standard treatment in CF, only few randomised trials comparing different antibiotic compounds exist.
Methods: We report on a prospective multicenter interventional trial of IV meropenem (120 mg/kg/day) or IV ceftazidime (200–400 mg/kg/
day), each administered together with IV tobramycin (9–12 mg/kg/day). Outcome measures were changes in lung function, microbiological
sputum burden and blood inflammatory marker. Liver and renal function values were measured to assess safety.
Results: One hundred eighteen patients (59/59) were included into the study with the following indications: first infection of P. aeruginosa
(n=6), acute pulmonary exacerbation (n=34) and suppression therapy of chronic P. aeruginosa colonization (n=78). Both treatments
improved lung function measures, bacterial sputum burden and CRP levels with no differences between treatment groups observed. A
significant higher elevation for alkaline phosphatase (pb0.0001) was observed for patients in the meropenem/tobramycin group.
Conclusions: IV antibiotic therapy in CF patients with meropenem/tobramycin is as effective as with ceftazidime/tobramycin regarding lung
function, microbiological sputum burden and systemic inflammatory status. Hepato-biliary function should be monitored carefully during IV
treatment, possibly important in CF patients with pre-existing liver disease.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Ceftazidime; Meropenem; Tobramycin; Safety1. Introduction
Respiratory infection results in progression of cystic
fibrosis (CF) lung disease [1]. Although the use of intra-
venous (IV) antibiotic agents for the treatment of acute
pulmonary exacerbations (APE) in CF patients has become
clinical practice [2], no consensus exists concerning the☆ This manuscript contains parts of the thesis of M. Fehling.
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doi:10.1016/j.jcf.2007.07.001exact regimen, duration or dosage of therapy [3]. Ceftazi-
dime and tobramycin is usually considered first-line therapy
[4] and results of larger trials of tobramycin regimens have
been published [5,6].
Recently, Blumer et al. reported a randomised compar-
ative trial that assessed the changes in pulmonary function,
clinical score and sputum microbacterial burden in 102 CF
patients receiving IV tobramycin with either meropenem or
ceftazidime to treat an acute exacerbation of CF lung disease
[7]. The authors concluded that both regimens improved
pulmonary and clinical status and reduced sputum bacterial
burden. They also reported that a larger proportion of
patients receiving meropenem/tobramycin therapy demon-
strated a satisfactory response in FEV1 [7]. In that study noed by Elsevier B.V. All rights reserved.
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inflammatory status or monitor safety parameters like liver
and kidney function tests.
The goal of this prospective randomised multicenter study
was to compare both efficacy and safety of the intravenous
antibiotic combinations meropenem/tobramycin versus cef-
tazidime/tobramycin in these CF patients, where this therapy
is widely used. Thus, differently to Blumer et al. [7], we
included also chronically colonized CF patients that received
routine intravenous antibiotic treatment and those patients
that received the treatment for eradication of first P.
aeruginosa infection.
2. Methods
2.1. Study design
This was a randomised prospective multicenter, open
labelled, interventional study. The goal was to compare
efficacy and safety of the antibiotic combinations merope-
nem/tobramycin (MER) versus ceftazidime/tobramycin
(CEF) for treatment of P. aeruginosa infection in CF patients.
2.2. Patient groups
Patients with CF were recruited from June 1997 to
September 1999. Indications for antibiotic treatment were
defined as (1) suppression therapy for chronic infection with
P. aeruginosawithout exacerbation of pulmonary symptoms,
(2) acute exacerbation of chronic pulmonary P. aeruginosa
infection and (3) eradication of P. aeruginosa after its first
detection in respiratory secretions. It was allowed to include
patients more than one time if the interval between the
treatments was at least 8 weeks. Length of the therapy was
determined clinically, outcome parameters were measured
before and after treatment.
Inclusion criteria were age older than five years for
indications (1) and (2) and older than two years for indication
(3), evidence for infection with P. aeruginosa and suscep-
tibility of the bacterial strains to the administered antibiotics.
Oral or inhalative antibiotic therapy had to be stopped at least
five days prior to study begin. Exclusion criterion was usage
of oral steroids or non-steroidal-anti-inflammatory therapy.
2.3. Treatment
The patients were randomised to IV treatment with
meropenem (Meronem®; AstraZeneca, Wedel, Germany)
plus tobramycin (Gernebcin®) or ceftazidime (Fortum®)
plus tobramycin for two to three weeks.
Intravenous meropenem was administered by infusion at a
dose of 120 mg/kg given divided into 3 daily doses (if
bodyweight was N50 kg, 2 g ofmeropenemwere administered
thrice a day), intravenous ceftazidime was given at 200–
400 mg/kg per day given in two or three daily doses and
intravenous tobramycin was given at a dose of 9–12 mg/kgper day in two doses. The dosage was adjusted after 4–7 days
to obtain tobramycin trough levels of less than 2 mg/dl.
2.4. Clinical measures
Pulmonary function testing was performed before and
after treatment (body plethysmography, Jaeger, Viasys
healthcare, Würzburg, Germany). FEV1, FVC and forced
expiratory flow 25% (MEF25%) were collected.
2.5. Bacteriological measures
Sputum samples for culture were collected from each
patient before start of the treatment and after the end of the trial.
Sputum samples were obtained by deep spontaneous expec-
toration or deep throat swabbing, if spontaneous expectoration
did not produce any sputum. Specimens were transported on
charcoal agar for P. aeruginosa and other microorganisms
(TransgermGO,Merck, Darmstadt, Germany). The number of
different P. aeruginosa isolates and quantitative P. aeruginosa
was determined by routine methods [8].
2.6. Inflammatory measures
Changes in C-reactive protein (CRP) and leukocyte count
were regarded as main outcome parameter for assessment of
general inflammatory status and measured before and after
treatment.
2.7. Safety measures
To assess the safety of the therapeutic regimens, alkaline
phosphatase (AP), serum glutamic oxaloacetic transaminase
(GOT) and serum glutamic pyruvic transaminase (GPT) as
liver function laboratory parameters were measured before
and after therapy. Analysis was performed as comparison of
mean difference between treatment groups. As additional
measures of safety, the level of creatinine, full blood count
and the number of recorded adverse effects, independently of
their nature, were compared between treatment groups.
2.8. Statistical analysis
Analysis was performed by calculation of the mean
difference between treatment groups and comparison by
unpaired t-test taking into account unequal variances. Exact
two-sided p-values are given for p-values below 0.05, which
were regarded as significant. Data analyses were performed
using STATA version 8.2 for Windows (STATA Corporation,
College Station, TX, USA).
3. Results
127 patients were enrolled into this study in total, 64 in
the CEF group, 63 in the MER group. Four and five pa-
tients respectively were excluded, as they did not fulfil the
Table 1
Summary of patient population, demographic and characteristics at baseline
MER CEF
Indications 59 59
(1) Suppression 36 42
(2) Exacerbation 20 14
(3) Eradication 3 3
Age (years) 17.3 (8.7) 16.9 (7.7)
Age groups (years)
0–6 5 5
7–12 14 10
13–18 10 20
N18 30 24
Male gender 29 30
Weight (kg) 42.0 (17.4) 43.3 (18.4)
FEV1 [%-pred] 52.2 (27.1) 55.3 (24.8)
FVC [%-pred] 68.5 (24.9) 66.4 (20.6)
MEF25 [%-pred] 20.1 (19.2) 23.8 (24.7)
Ps types [number] 2.46 (1.22) 2.41 (1.37)
Ps CFUs [108/g sputum] 2.37 (2.73) 2.07 (2.58)
Demographic data are given in absolute numbers; characteristics data are
given as mean and standard deviation in parenthesis.
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aeruginosa, two patients had also been prescribed additional
oral antibiotics and in two patients the IV antibiotic therapy
was changed during the trial), leaving 59 patients in each
treatment group for intention to treat analysis. Details of the
baseline demographics are given in Table 1, showing no
differences between the treatment groups.
3.1. Efficacy
Results of efficacy measures are reported in Table 2a.
Taken together, there was a significant improvement for lung
function values and a significant reduction in bacterial
sputum burden and systemic inflammatory status between
before and after treatment for both treatment groups. For
none of these efficacy measures a significant difference
between treatment groups was found (Table 2a).
Results were not different for subgroup analysis accord-
ing to indication as shown in detail for the subgroup of CFTable 2a
Efficacy of IV meropenem/tobramycin compared to IV ceftazidime/tobramycin in C
59 in the CEF group)
MER pre a MER post a CEF pre a
FEV1 [%-pred] 52.2 (27.1) 57.3 (26.8) 55.3 (24.8)
FVC [%-pred] 68.5 (24.9) 72.4 (22.9) 66.4 (20.6)
MEF25 [%-pred] 20.1 (19.2) 21.3 (20.8) 23.8 (24.7)
Ps types [number] 2.46 (1.22) 1.65 (1.16) 2.41 (1.37)
Ps CFUs [108/g sputum] 2.37 (2.73) 1.26 (2.06) 2.07 (2.58)
Leucocytes [G/l] 10.6 (3.98) 9.89 (3.12) 11.3 (5.49)
CRP [mg/l] 18.8 (25.4) 12.1 (18.3) 21.4 (36.7)
a The mean (±SD) is given for baseline values (pre) and values after therapy (p
b The difference of the change between MER and CEF is given as mean differenc
parameters was calculated as percentage change from baseline. None of the differe
account unequal variances b0.05).patients that received IV antibiotics as prophylactic suppres-
sion therapy for chronic P. aeruginosa infection (Table 2b).
3.2. Safety
3.2.1. Side effects
Safety data from all enrolled patients who received at least
one dose of study medication demonstrated that there were a
similar proportion of patients with adverse effects attributed
to the medication, i.e. side effects in both treatment groups.
Side effects occurred in 11 patients of the MER group
(nausea in 2 patients; headache in 2 patients; diarrhoea in 3
patients; allergic reactions in 2 patients, in one of these this
led to the withdrawal from the study; nose bleeding in one
patient and fatigue in one patient) and in 10 patients of the
CEF group (nausea in 3 patients, one of these had to stop the
study; headache in one patient; diarrhoea in 3 patients;
allergic reaction in one patient; acute pancreatitis in one
patient and recurrent problems with the IV-line in another
patient; both side effects leading to withdrawal from the
study in these subjects).
3.2.2. Liver and renal function tests and blood count
Results of liver and renal functions tests as well as blood
count are reported in Table 3. Taken together, there was no
significant difference between treatment groups for any of
the parameters, except for AP levels, with a decrease in the
CEF group and an increase in the MER group (Table 3).
When safety measures were examined only in the
subgroup of CF patients that received IV antibiotics as
prophylactic suppression therapy for chronic P. aeruginosa
infection, no differences between treatment groups were
observed for any of the safety measures (data not shown).
4. Discussion
This prospective randomised clinical trial examined the
efficacy and safety of intravenous antibiotic combination
therapy in CF patients. Both combinations resulted in
improvements of pulmonary function, bacteriological spu-
tum burden and systemic inflammatory status. Whereas noF patients for the ITT group and all indications (n=59 in the MER group and
CEF post a Difference between treatment groups (MER-CEF) b
61.4 (25.8) 7.49 (−10.44 to +25.43)
71.2 (21.0) 1.22 (−6.54 to +8.99)
29.1 (27.2) 4.71 (−29.73 to +39.16)
1.64 (1.24) −0.13 (−0.62 to +0.37)
0.55 (0.94) 1.09 (−0.12 to +2.30)
9.72 (5.48) 0.86 (−0.50 to +2.23)
11.0 (20.1) 7.01 (−4.98 to +19.01)
ost) for the respective treatment regimen.
e with 95%-confidence intervals in parentheses. The change in lung function
nces were statistically significant (p-value derived from the t-test taking into
Table 2b
Efficacy of IV meropenem/tobramycin compared to IV ceftazidime/tobramycin in CF patients of the routine suppression group only (n=36 in the MER group
and 42 in the CEF group)
MER pre a MER post a CEF pre a CEF post a Difference between treatment groups (MER-CEF) b
FEV1 [%-pred] 54.3 (22.9) 59.8 (23.9) 54.9 (25.9) 61.6 (25.4) −0.96 (−12.29 to +10.37)
FVC [%-pred] 64.7 (19.9) 70.5 (19.5) 67.7 (22.0) 72.7 (20.7) 1.95 (−8.16 to +12.05)
MEF25 [%-pred] 25.5 (19.9) 28.6 (22.5) 20.4 (24.7) 24.8 (26.2) −12.35 (−40.12 to +15.42)
Ps types [number] 2.44 (1.31) 1.71 (1.36) 2.37 (1.24) 1.47 (1.02) 0.07 (−0.58 to +0.73)
Ps CFUs [108/g Sputum] 2.67 (3.39) 0.56 (0.63) 1.82 (1.70) 1.05 (2.26) −1.47 (−3.17 to +0.23)
Leucocytes [G/l] 10.7 (4.66) 9.21 (3.46) 11.5 (5.70) 10.23 (6.04) −0.41 (−2.18 to +1.36)
CRP [mg/l] 14.6 (16.9) 9.7 (19.1) 23.6 (42.9) 9.98 (15.9) 8.52 (−7.08 to +24.12)
See footnotes of Table 2a for explanation.
Table 3
Safety of IV meropenem/tobramycin compared to IV ceftazidime/
tobramycin in CF patients for the ITT group and all indications
MER
pre a
MER
post a
CEF
pre a
CEF
post a
Difference between treatment
groups (MER-CEF) b
AP [U/l] 278
(141)
298
(154)
272
(128)
253
(126)
60.63 (37.13 to 84.14) ⁎
GOT [U/l] 14.2
(6.2)
17.2
(9.8)
14.3
(5.2)
15.3
(8.8)
2.37 (−0.39 to +5.13)
GPT [U/l] 17.8
(13.1)
22.8
(13.7)
18.2
(8.6)
21.9
(13.2)
1.89 (−3.36 to +7.15)
Haemoglobin
[g/dl]
13.5
(1.39)
13.3
(1.25)
13.7
(1.54)
13.4
(1.66)
0.08 (−0.35 to +0.50)
Platelets
[G/l]
324
(99)
293
(92)
286
(96)
261
(88)
−8.0 (−36.1 to +20.1)
Creatinine
[mg/dl]
0.62
(0.20)
0.64
(0.25)
0.64
(0.23)
0.65
(0.23)
0.03 (−0.05 to +0.10)
a The mean (±SD) is given for baseline values (pre) and values after
therapy (post) for the respective treatment regimen.
b The difference of the change between MER and CEF is given as mean
difference with 95%-confidence intervals in parentheses.
⁎ Indicates a statistical significant difference between groups (p-value
derived from the t-test taking into account unequal variances b0.05).
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efficacy outcomes, patients of the meropenem group showed
a higher increase in AP values compared to patients of the
ceftazidime group.
Morbidity and mortality in patients with CF is mainly due
to a chronic relapsing bronchopulmonary infection caused by
P. aeruginosa [1,9]. Therefore cystic fibrosis patients often
require life-long repeated courses of intravenous antibiotic
treatment for many years. Nevertheless, only very sparse data
on efficacy and safety of these widely used antibiotic treatment
combinations are available fromCF patients, randomised trials
including different treatment regimens are either not compar-
ing antibiotic combination therapies or include only low
numbers of patients [10–14]. Thus, this trial with 118 patients
is one of the largest prospective studies comparing parenteral
combination antibiotic therapy in CF patients. A recent report
of Blumer et al. studied in a comparable design CF patients
suffering from acute pulmonary exacerbations [7]. They found
a significant improvement from baseline for pulmonary
function and no difference between treatment groups for any
of the examined lung function values. We confirm these
findings in a different CF population, being of importance, as it
is well known that patients from different CF populations and
centers show variability e.g. in microbiological colonization
[15] and their genetic background [16]. As two thirds of our
patients were included for suppression therapy of chronic
infection with P. aeruginosa without exacerbation of pulmo-
nary symptoms, we expand this knowledge to a different
patient group. This helps to appraise the regular prophylactic
use of intravenous antibiotic therapy in general and specifi-
cally the use of meropenem in combination with tobramycin.
There are some differences between our results and the
results reported by Blumer et al. They found a higher
treatment response for FEV1 (relative change of 29.4 and
38.8%-predicted versus 13.0 and 20.4%-predicted in our
study) and reported more adverse events due to elevated liver
function tests [7]. Although we can only speculate, we
suspect differences in patient demographics, disease state,
organ involvement or concomitant therapy to be the reason
for these differing results.
A decrease for AP was seen in the patients of the CEF
group compared to an increase in the patients of the MER
group. Blumer et al. also reported 4-times more adverseevents due to AP increase in the MER group compared to the
CEF group [7]. Although this might indicate a higher hepato-
biliary toxicity of meropenem compared to ceftazidime,
which has also been reported for CF patients by others [12],
these findings have to be interpreted carefully. The source of
elevated AP is not defined and may be liver, intestine or
bone, especially in growing children [17]. Elevation of AP is
a relatively common finding, especially in adolescence and
in CF patients [18,19], and as such does not generally
indicate the presence of hepato-biliary disease [20].
Irrespective of the source of the AP, during intravenous
treatment with meropenem and tobramycin liver enzymes
should be monitored carefully, even more carefully in CF
patients with predisposition to liver damage or pre-existing
liver disease.
With the results of this prospective multicenter open-label
interventional study, we demonstrate that meropenem in
combination with tobramycin is as useful for treatment of
P. aeruginosa infection in cystic fibrosis patients as ceftazi-
dime with tobramycin. In addition to its clinical efficacy,
we demonstrate for the first time a direct anti-pseudomonal
146 P. Latzin et al. / Journal of Cystic Fibrosis 7 (2008) 142–146effect of the MER combination in vivo. Although the clinical
relevance of the AP increase in the meropenem group is not
known yet, we suggest to use meropenem in a cautious way
and to monitor liver function.
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